Published in J Infect Dis on April 23, 2003
Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother (2013) 1.03
Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol (2005) 0.96
Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One (2013) 0.89
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother (2013) 0.89
Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PLoS One (2012) 0.88
Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ (2008) 0.87
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther (2015) 0.81
Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother (2013) 0.76
Immunizations for renal transplant candidates and recipients. Nat Clin Pract Nephrol (2008) 0.75
Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia. Clin Vaccine Immunol (2016) 0.75
Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines. Int J Mol Sci (2016) 0.75
Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis. Clin Vaccine Immunol (2016) 0.75
Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study. Transpl Int (2017) 0.75
Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med (2002) 9.21
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ (2003) 3.03
Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Med (2014) 2.70
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation (2013) 2.43
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol (2007) 2.35
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2004) 2.23
Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation (2004) 2.11
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis (2010) 1.98
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 1.94
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis (2009) 1.64
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer (2002) 1.50
Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care (2007) 1.48
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant (2005) 1.45
Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol (2008) 1.43
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med (2008) 1.38
Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis (2002) 1.37
A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation (2010) 1.35
Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis (2012) 1.25
Emerging fungal infections in immunocompromised patients. F1000 Med Rep (2011) 1.18
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis (2005) 1.14
State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis (2012) 1.10
A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant (2004) 1.09
Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol (2010) 1.09
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis (2004) 1.08
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother (2006) 1.07
The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation (2011) 1.07
Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation (2005) 1.05
A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis (2005) 1.05
Antibiotic prophylaxis for total joint replacement surgery: results of a survey of Canadian orthopedic surgeons. Can J Surg (2009) 1.05
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther (2009) 1.05
Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation (2005) 1.02
Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation (2012) 1.00
A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis (2007) 1.00
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Med (2008) 0.98
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet (2005) 0.98
Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J Clin Virol (2002) 0.97
An international survey of cytomegalovirus management practices in lung transplantation. Transplantation (2010) 0.97
A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation (2007) 0.97
Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. J Clin Microbiol (2008) 0.97
Treatment of candiduria with micafungin: A case series. Can J Infect Dis Med Microbiol (2007) 0.97
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation (2004) 0.95
Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis (2008) 0.95
Unrecognized pretransplant and donor‐derived cryptococcal disease in organ transplant recipients. Clin Infect Dis (2010) 0.94
Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother (2007) 0.94
Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis (2005) 0.93
Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation (2003) 0.93
Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis (2010) 0.93
Graphium basitruncatum fungemia in a patient with acute leukemia. J Clin Microbiol (2007) 0.93
Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis (2013) 0.92
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation (2005) 0.92
Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation (2008) 0.92
Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation (2011) 0.91
Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry? Am J Transplant (2003) 0.91
A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis (2008) 0.90
A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant (2011) 0.89
Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation (2013) 0.88
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics (2011) 0.87
Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant (2011) 0.87
The production of transgenic pigs for potential use in clinical xenotransplantation: microbiological evaluation. Xenotransplantation (2002) 0.86
Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant (2006) 0.85
Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med (2004) 0.85
An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis (2009) 0.84
Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant (2008) 0.84
Pharmacoeconomic assessment of therapy for invasive aspergillosis. Mycoses (2013) 0.84
The production of transgenic pigs for potential use in clinical xenotransplantation: baseline clinical pathology and organ size studies. Xenotransplantation (2002) 0.84
An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One (2012) 0.83
The relationship between Candida species cultured from the respiratory tract and systemic inflammation in critically ill patients with ventilator-associated pneumonia. Can J Anaesth (2010) 0.83
Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. Pediatr Transplant (2010) 0.82
Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation (2014) 0.82
Life-threatening infection in transplant recipients. Crit Care Clin (2013) 0.82
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis (2011) 0.82
Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol (2010) 0.82
Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis. Transplantation (2012) 0.82
Long term immune responses to pandemic influenza A/H1N1 infection in solid organ transplant recipients. PLoS One (2011) 0.82
Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am (2010) 0.82
A novel model to study bacterial adherence to the transplanted airway: inhibition of Burkholderia cepacia adherence to human airway by dextran and xylitol. J Heart Lung Transplant (2004) 0.82
Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. Transplantation (2016) 0.81
Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study. Leuk Lymphoma (2012) 0.80
Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. Mycoses (2013) 0.80
Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis (2002) 0.80
Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period. Transplantation (2014) 0.79
Microbial contamination of clinical islet transplant preparations is associated with very low risk of infection. Diabetes Technol Ther (2013) 0.79
Human cytomegalovirus infection in humanized liver chimeric mice. Hepatol Res (2013) 0.79
Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant (2003) 0.79
Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology. J Heart Lung Transplant (2009) 0.79
Cytomegalovirus prophylaxis: how long is enough? Nat Rev Nephrol (2010) 0.79
Comparison of hospitalized solid organ transplant recipients and nonimmunocompromised patients with pandemic H1N1 infection: a retrospective cohort study. Transplantation (2011) 0.79
Modulation of the inhibitory receptor leukocyte Ig-like receptor 1 on human natural killer cells. Front Immunol (2011) 0.78
Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. J Clin Virol (2012) 0.78
Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation (2010) 0.78
Severe acute respiratory syndrome and the liver. Hepatology (2004) 0.78
Treatment of cytomegalovirus disease in solid organ transplant recipients: markers of inflammation as predictors of outcome. Transplantation (2012) 0.78
Mold infections in lung transplant recipients. Semin Respir Crit Care Med (2013) 0.78
Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol (2012) 0.78
Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. Transplantation (2010) 0.78
Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma. PLoS One (2013) 0.78